Copyright © 1998 by Institute of Pharmacology
Polish Academy of Sciences
Pol. J. Pharmacol., 1998, 50, 107-115
ISSN 1230-6002

Go to: Contents | Previous Article | Next Article | PJP - Home Page |


PHARMACOLOGICAL PROFILE OF VENLAFAXINE, A NEW ANTIDEPRESSANT, GIVEN ACUTELY
Zofia Rogóż#, Marta Dziedzicka-Wasylewska, Jerzy Maj
Institute of Pharmacology, Polish Academy of Sciences, Smętna 12, PL 31-343 Kraków, Poland

Pharmacological proflile of venlafaxine, a new antidepressant, given acutely. Z. ROGÓŻ, M. DZIEDZICKA-WASYLEWSKA, J. MAJ. Pol. J. Pharmacol., 1998, 50, 107-115.

Pharmacological effects of acute treatment with venlafaxine (VEN), a clinically active antidepressant [a noradrenaline (NA) and 5-hydroxytryptamine (5-HT) reuptake inhibitor without any affinity for neurotransmitter receptors] were studied in mice and rats. VEN inhibited the reserpine- or apomorphine-induced hypothermia and enhanced the L-5-HTP-induced head twitches in mice. It reduced the immobility time in Porsolt’s test in mice and rats, but either did not change the locomotor activity (mice) or decreased it (rats). VEN reduced the locomotor hyperactivity induced by amphetamine (AMP), apomorphine (APO) and quinpirole (QUI), as well as the APO-induced stereotypy; the stereotypy induced by AMP in rats was prolonged. VEN neither changed the clonidine-induced aggressiveness in mice nor the behavioral syndrome induced by oxotremorine in rats.
The obtained results indicate that VEN, given acutely, shows a pharmacological profile similar to that of tricyclic NA and 5-HT reuptake inhibitors. In contrast to the antidepressants mentioned above, VEN does not exhibit an alpha1-adrenolytic or a cholinolytic activity (in vivo tests).

Key words: arginine-vasopressin, NMDA, MK-801, AP-7, arcaine, HA-966, memory

  # correspondence
Back to: Top | PJP - Home Page |